Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases
Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…